Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 18 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus will manufacture the product, while Torrent will market it under its brand name, leveraging its strong presence in chronic therapies. Zydus will market the product under its own brand names, enhancing patient convenience with a reusable pen device.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases